Pathway-Targeted Pharmacogenomics of CYP1A2 in Human Liver.
about
Transcriptional profiling of human liver identifies sex-biased genes associated with polygenic dyslipidemia and coronary artery diseaseInvestigation of the major cytochrome P450 1A2 genetic variant in a healthy Tibetan population in China.MIRNA-DISTILLER: A Stand-Alone Application to Compile microRNA Data from Databases.Influence of environmental and genetic factors on CYP1A2 activity in individuals of South Asian and European ancestry.Diurnal variation in CYP1A2 enzyme activity in South Asians and Europeans.The truncated splice variant of peroxisome proliferator-activated receptor alpha, PPARα-tr, autonomously regulates proliferative and pro-inflammatory genesPharmGKB summary: very important pharmacogene information for CYP1A2.Activation of aflatoxin B1 by expression of human CYP1A2 polymorphisms in Saccharomyces cerevisiae.Pharmacogenomics of Cytochrome P450 3A4: Recent Progress Toward the "Missing Heritability" ProblemGenetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1Cytochrome P450 3A4*22, PPAR-α, and ARNT polymorphisms and clopidogrel responseIdiosyncratic Drug-Induced Liver Injury (IDILI): Potential Mechanisms and Predictive Assays.In vitro analysis of factors influencing CYP1A2 expression as potential determinants of interindividual variation.Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia.Influence of ethnicity on response to asthma drugs.Gene copy number variation analysis reveals dosage-insensitive expression of CYP2E1.Methyleugenol DNA adducts in human liver are associated with SULT1A1 copy number variations and expression levels.Quantitative Evaluation and Prediction of Drug Effects and Toxicological Risk Using Mechanistic Multiscale Models.Association between CYP2E1 polymorphisms and risk of differentiated thyroid carcinoma.Peroxisome proliferator-activated receptor alpha, PPARα, directly regulates transcription of cytochrome P450 CYP2C8.Genome-wide association study of caffeine metabolites provides new insights to caffeine metabolism and dietary caffeine-consumption behavior.Population pharmacokinetic study of memantine: effects of clinical and genetic factors.ABCC11/MRP8 polymorphisms affect 5-fluorouracil-induced severe toxicity and hepatic expression.Cytochrome P450 and Non-Cytochrome P450 Oxidative Metabolism: Contributions to the Pharmacokinetics, Safety, and Efficacy of Xenobiotics.The AhRR-c.565C>G transversion may increase total antioxidant capacity levels of the seminal plasma in infertile men.The impact of genetic polymorphisms on CYP1A2 activity in humans: a systematic review and meta-analysis.Associations of CYP1A2 Polymorphisms with the Risk Haplotypes in Lung Cancer in the Slovak Population.Decreased expression of hepatic cytochrome P450 1A2 (CYP1A2) in a chronic intermittent hypoxia mouse model.
P2860
Q28476544-3B6C584A-BA7D-4043-AFC7-026737CD6FC6Q33828034-93EBC9CD-924A-4310-936B-97C0B29DC7C4Q34149913-2A486703-ED4C-458D-8532-4CD80070FB63Q34297580-A0EE7254-2D5F-4D37-A8F1-EFB49B98FD74Q34320302-DA26AE9F-B30C-491B-8F82-479F2606A55EQ35677612-A6E212AD-0F37-4F11-A83E-97B22F9C57ADQ35940452-311EA922-EBEC-4E75-AFE8-F4519F60A06DQ36450003-7D733CC7-614A-434A-8C21-4640A99A2185Q36634077-96CADC11-D9D3-48F8-A3AC-EE54A704C100Q36998199-CBB45191-AAF7-42BD-A517-E2308B0BA1CFQ37390889-E262DF1D-D944-4D6E-B68D-58605C199329Q37590883-6615BA17-BDBF-4CB1-8DB6-931486861612Q37724295-3D3579C1-D313-46C8-96F6-02C66A62A5ECQ38103885-402F2DC1-A772-4619-AB41-707E3D5690E3Q38494683-46A7B349-0CE2-4D26-82B1-C044C957AD93Q38824701-D73772AC-71D9-4510-BD34-F1E010C98E7DQ38888279-0CBD32BA-5EDF-4A1B-AF69-E505D9C85B2CQ38915439-78ADD143-A074-4D22-8D69-A5B0224DB523Q40091055-73892022-22A4-4842-9F7A-F7EFE1DDD38EQ40305168-CB22614D-858B-4C2F-8C4A-57861465EBD0Q40554461-05B95DA6-0DF7-493B-AF4F-A5C4E4B54859Q43752615-8FC4377E-06CA-4929-8265-EFAF3E865E3CQ45899283-B0CD723F-7157-4B66-90DD-984C51B804AFQ46076879-B5CBF4E4-05FD-45D6-BC52-DC6B5E7A3F76Q46354354-80DEA455-CAEC-4CA1-9476-44335AD733D6Q49546782-8C4C1933-D7AA-407F-BD23-B02AE62827FDQ53145173-CC0DAB0A-B43C-4362-BE3F-DA517AEDF6E7Q55000530-DA6494B6-6C28-4C13-8E3B-A518FF37F5B8
P2860
Pathway-Targeted Pharmacogenomics of CYP1A2 in Human Liver.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Pathway-Targeted Pharmacogenomics of CYP1A2 in Human Liver.
@ast
Pathway-Targeted Pharmacogenomics of CYP1A2 in Human Liver.
@en
type
label
Pathway-Targeted Pharmacogenomics of CYP1A2 in Human Liver.
@ast
Pathway-Targeted Pharmacogenomics of CYP1A2 in Human Liver.
@en
prefLabel
Pathway-Targeted Pharmacogenomics of CYP1A2 in Human Liver.
@ast
Pathway-Targeted Pharmacogenomics of CYP1A2 in Human Liver.
@en
P2093
P2860
P356
P1476
Pathway-Targeted Pharmacogenomics of CYP1A2 in Human Liver
@en
P2093
Kathrin Klein
Matthias Schwab
Stefan Winter
P2860
P356
10.3389/FPHAR.2010.00129
P577
2010-11-02T00:00:00Z